trending Market Intelligence /marketintelligence/en/news-insights/trending/RDrppFqmlaMNlHRPd4vFfQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Gilead seeks US FDA approval for filgotinib to treat rheumatoid arthritis

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Gilead seeks US FDA approval for filgotinib to treat rheumatoid arthritis

Gilead Sciences Inc. filed an application with the U.S. Food and Drug Administration seeking approval for filgotinib to treat adult patients with rheumatoid arthritis.

Rheumatoid arthritis is an autoimmune disorder characterized by the immune system mistakenly attacking healthy tissues, resulting in pain, swelling and stiffness in the joints.

The Foster City, Calif.-based drugmaker submitted a priority review voucher along with its new drug application, shortening the regulator's review time.

The application is supported by the global phase 3 Finch studies, which evaluated the medicine in a total of 3,452 patients with moderate to severely active rheumatoid arthritis. The studies met their primary goals as the medication was well tolerated and effective in treating the patients.

Gilead and Belgium's Galapagos NV are jointly developing and commercializing filgotinib under a deal signed in December 2015.

Filgotinib, which inhibits an enzyme called Janus kinase 1, is not yet approved anywhere in the world.

The European Medicines Agency is currently reviewing Gilead's marketing application for filgotinib. The company has also filed an application with the Japanese Ministry of Health, Labor and Welfare.